Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
已完结20由 不可二二 发布于 2025/11/16 14:08:42
DOI:10.1016/s0140-6736(25)01720-9
作者:Zheng Wang, Jia Fan, Shaolai Zhou, Yunfan Sun, Fei Liang, Yuan Ji, Fangming Gu, Tao Li, Li Peng, Tao Peng, Xiaolun Huang, Zhenbin Ding, Dousheng Bai, Bangde Xiang, Guang Tan, Tianfu Wen, Yongyi Zeng,
文献类型:期刊论文
补充材料:仅需补充材料